The real question for any prevention program’s economics isn’t the per-member price. It’s whether the program actually lowers the total healthcare spend under a contract that’s built to pay for that specific outcome. This one distinction changes everything about how we talk about healthcare AI unit economics, moving the goalposts from enrollment numbers to a verifiable financial impact.
The Contract Question: From Seat Billing to Outcome Risk
In the end, the unit economics of prevention programs boil down to a single question, one made brutally clear by the Centers for Medicare and Medicaid Services (CMS) Medicare Shared Savings Program (MSSP) record: does your program cut total spend under a contract that pays for that reduction? CMS MSSP program details. For years, prevention programs ran on a simple per-seat billing model. You got paid for signing people up, and it didn’t matter what happened to them afterwards or if any costs were saved downstream. Of course, this meant there was no way to prove the program’s effect on the overall cost curve which made it nearly impossible for a plan’s finance team or any serious healthcare investor to model a true return on investment (ROI). The move to outcome-risk contracts completely upends this. In these deals, vendors take on a piece of the financial risk, which means their pay is directly connected to hitting pre-set health or cost-saving targets. This forces vendor incentives to align with payer goals, making them deliver measurable results that affect the total cost of care. For any healthcare AI in prevention, its profitability and long-term survival are now judged by its ability to generate savings you can actually verify, not just by its adoption rate.
The Recorded Evidence Base: Omada Health’s DPP Outcomes Study
Omada Health’s Diabetes Prevention Program (DPP) Outcomes Study is a perfect example of this evidence-first world. The study is the company’s recorded proof for its argument that it can reduce total spend. Instead of just modeling out potential savings or using projections, Omada built its entire case on the published trial outcomes from its CDC-recognized program, giving them a solid, peer-reviewed foundation to stand on when talking about effectiveness. Omada Health, which was funded by Oak HC/FT and went public on Nasdaq in June 2025 with a $150 million IPO, is a chronic care platform that has committed to this kind of evidence-based validation. Their focus on published trial outcomes, which you can find on ClinicalTrials.gov and PubMed Omada Health DPP study results, gives plan finance teams hard data to work with when they’re trying to calculate potential ROI. This is a world away from approaches based on less rigorous methods or a vendor’s own claimed projections, which just don’t have the independent verification investors need to feel confident. Having recorded, peer-reviewed outcomes is how you build credibility in prevention, especially when the long-term cost impact is so difficult to measure.
The Peer Set Under the Same Test: Hinge Health and Spring Health
This demand to show outcome-driven value is hitting the entire prevention sector, with companies like Hinge Health and Spring Health facing the same level of scrutiny in their own categories. These peers show a market-wide shift toward contracts where the vendor has to carry outcome risk, a clear sign the digital health market is growing up. Hinge Health, pulling in $123.8 million in Q1 2025 revenue, and Spring Health, with its $3.3 billion valuation in 2024, are being judged on their ability to produce measurable cost reductions. Both are subject to the same tough ROI methodology comparisons as Omada, including matched-pair analyses, randomized controlled trials (RCTs), and retrospective studies. Why? Because investors and finance teams need these comparisons to figure out which ROI methodology they can actually trust when they’re looking at different digital health vendors ROI methodology comparison in digital health. The change in how contracts are written means a program’s value is decided by its power to bend the overall cost curve, not by its per-member per-year (PMPY) price tag. For instance, Spring Health is used as an ROI benchmark with its reported $1.90:$1 return, putting it in the same financial outcome conversations as Hinge Health (3.0x). The new standard for prevention program economics is tangible financial returns. Engagement metrics and perceived benefits are secondary.
Measuring Healthcare AI ROI: The Cost Curve Test
The entire field of prevention unit economics now turns on this move toward outcome-risk contracts. For healthcare AI, this means profitability and impact are completely tied to a program’s demonstrated ability to bend the cost curve. A program that just bills per seat, with no way to connect payment to a drop in total spend, can’t prove it changed healthcare costs at all. This requires strong frameworks for measuring healthcare AI ROI. These models have to go way past simple per-member savings math and capture the wider financial effect on an entire population or health plan. Key metrics for judging healthcare AI profitability in prevention now include:
- Total Cost of Care Reduction: Can you show direct proof that the program lowered overall healthcare spending for the people enrolled?
- Inpatient Utilization Reduction: A drop in hospital admissions and readmissions, which are huge cost drivers. Hello Heart’s peer-reviewed data, for example, showed a 47% inpatient reduction and $1,709 in per-member savings, that’s the kind of outcome that gets attention.
- Chronic Disease Management Improvement: Did quantifiable disease markers (like HbA1c for diabetes or blood pressure for hypertension) get better, which would correlate with fewer long-term complications and costs?
- Return on Investment (ROI) Ratio: A straightforward financial calculation showing the money returned for every dollar put into the program.
These metrics, all based on recorded trial outcomes and actual contract figures, create the transparency that plan finance teams and healthcare investors need to model prevention program economics accurately. The old “per-seat” billing for prevention is being replaced by a performance-based model. True value is measured by a program’s verifiable impact on the cost curve. That’s the real test for any healthcare AI trying to generate a high ROI in prevention.
Frequently Asked Questions
How do prevention programs demonstrate economic viability to plan finance teams and healthcare investors?
Economic viability is demonstrated by reducing total healthcare spend under contracts that reward such outcomes, rather than simply by a per-member price tag. This shifts the focus from enrollment numbers to verifiable financial impact, often through outcome-risk contracts where vendors assume financial risk tied to cost-saving metrics.
What is ‘outcome risk’ in the context of prevention program contracts?
Outcome risk refers to contract structures where vendors’ compensation is directly tied to achieving pre-defined health or cost-saving metrics. This aligns vendor incentives with payer objectives, compelling programs to deliver measurable results that impact the total cost of care, rather than just billing per enrolled member.
What kind of evidence is considered robust for evaluating the effectiveness of prevention programs?
Robust evidence includes published trial outcomes, such as those from randomized controlled trials (RCTs) and retrospective studies, rather than modeled savings or projections. The Omada Health Diabetes Prevention Program Outcomes Study, based on peer-reviewed results, exemplifies this foundational evidence.
How do companies like Omada Health, Hinge Health, and Spring Health demonstrate their value?
These companies demonstrate value by providing concrete data from published trial outcomes and undergoing rigorous ROI methodology comparisons. Their ability to deliver measurable cost reductions and tangible financial returns, such as reported ROI benchmarks, is crucial for investor and finance team assessment.
